Cargando…

Synthetic Toll Like Receptor-4 (TLR-4) Agonist Peptides as a Novel Class of Adjuvants

BACKGROUND: Adjuvants serve as catalysts of the innate immune response by initiating a localized site of inflammation that is mitigated by the interactions between antigens and toll like receptor (TLR) proteins. Currently, the majority of vaccines are formulated with aluminum based adjuvants, which...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shanmugam, Arulkumaran, Rajoria, Shilpi, George, Andrea L., Mittelman, Abraham, Suriano, Robert, Tiwari, Raj K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282694/ https://www.ncbi.nlm.nih.gov/pubmed/22363498 http://dx.doi.org/10.1371/journal.pone.0030839

Ejemplares similares

Endothelial progenitor cell biology in disease and tissue regeneration
por: George, Andrea L, et al.
Publicado: (2011)

Estrogen Induced Metastatic Modulators MMP-2 and MMP-9 Are Targets of 3,3′-Diindolylmethane in Thyroid Cancer
por: Rajoria, Shilpi, et al.
Publicado: (2011)

Hypoxia and estrogen are functionally equivalent in breast cancer-endothelial cell interdependence
por: George, Andrea L, et al.
Publicado: (2012)

Synthetic glycan-based TLR4 agonists targeting caspase-4/11 for the development of adjuvants and immunotherapeutics
por: Adanitsch, Florian, et al.
Publicado: (2018)

Rational Design of a New Class of Toll-Like Receptor 4 (TLR4) Tryptamine Related Agonists by Means of the Structure- and Ligand-Based Virtual Screening for Vaccine Adjuvant Discovery
por: Honegr, Jan, et al.
Publicado: (2018)

Ex Vivo Derived Primary Melanoma Cells: Implications for Immunotherapeutic Vaccines
por: Suriano, Robert, et al.
Publicado: (2013)

Toll-Like Receptor 4 Expression on Lymphoma Cells Is Critical for Therapeutic Activity of Intratumoral Therapy With Synthetic TLR4 Agonist Glucopyranosyl Lipid A
por: Lu, Hailing, et al.
Publicado: (2020)

Skin scarification with Plasmodium falciparum peptide vaccine using synthetic TLR agonists as adjuvants elicits malaria sporozoite neutralizing immunity
por: Mitchell, Robert A., et al.
Publicado: (2016)

Molecular target based combinational therapeutic approaches in thyroid cancer
por: Rajoria, Shilpi, et al.
Publicado: (2012)

Discovery and Validation of a New Class of Small Molecule Toll-Like Receptor 4 (TLR4) Inhibitors
por: Neal, Matthew D., et al.
Publicado: (2013)

Lung and general health effects of Toll-like receptor-4 (TLR4)-interacting SPA4 peptide
por: Awasthi, Shanjana, et al.
Publicado: (2020)

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140
por: Arias, Mauricio A., et al.
Publicado: (2012)

A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity
por: Sato-Kaneko, Fumi, et al.
Publicado: (2020)

Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers
por: Mai, Chun Wai, et al.
Publicado: (2013)

Vaccine adjuvant activity of a TLR4-activating synthetic glycolipid by promoting autophagy
por: Chou, Yi-Ju, et al.
Publicado: (2020)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Molecular Signatures of a TLR4 Agonist-Adjuvanted HIV-1 Vaccine Candidate in Humans
por: Anderson, Jenna, et al.
Publicado: (2018)

Prevention and Mitigation of Acute Radiation Syndrome in Mice by Synthetic Lipopeptide Agonists of Toll-Like Receptor 2 (TLR2)
por: Shakhov, Alexander N., et al.
Publicado: (2012)

Physicochemical characterization of biological and synthetic forms of two lipid A-based TLR4 agonists
por: Hu, Gang, et al.
Publicado: (2023)

Toll-Like Receptor 4 (TLR4) and Typhoid Fever in Vietnam
por: Hue, Nguyen Thi, et al.
Publicado: (2009)

A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations
por: Van Hoeven, Neal, et al.
Publicado: (2016)

Molecular and Cellular Response Profiles Induced by the TLR4 Agonist-Based Adjuvant Glucopyranosyl Lipid A
por: Lambert, Stacie L., et al.
Publicado: (2012)

Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma
por: Pan, Caixu, et al.
Publicado: (2022)

TLR4-dependent activation of dendritic cells by an HMGB1-derived peptide adjuvant
por: Saenz, Rebecca, et al.
Publicado: (2014)

A Novel Class of Small Molecule Agonists with Preference for Human over Mouse TLR4 Activation
por: Marshall, Jason D., et al.
Publicado: (2016)

Phylogenetic variation and polymorphism at the Toll-like receptor 4 locus (TLR4)
por: Smirnova, Irina, et al.
Publicado: (2000)

Toll-Like Receptor 4 (TLR4) and AMPK Relevance in Cardiovascular Disease
por: Vaez, Haleh, et al.
Publicado: (2023)

Toll-like receptor 4 (TLR4): new insight immune and aging
por: Kim, Hyo-Jin, et al.
Publicado: (2023)

Dietary Silk Peptide Inhibits LPS-Induced Inflammatory Responses by Modulating Toll-Like Receptor 4 (TLR4) Signaling
por: Chei, Sungwoo, et al.
Publicado: (2020)

Lipid A Mimetics Based on Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants
por: Strobl, Sebastian, et al.
Publicado: (2022)

New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants
por: Romerio, Alessio, et al.
Publicado: (2023)

TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
por: Luchner, Marina, et al.
Publicado: (2021)

NOD2 Agonist Promotes the Production of Inflammatory Cytokines in VSMC in Synergy with TLR2 and TLR4 Agonists
por: Sun, Jinghua, et al.
Publicado: (2012)

Formulated Phospholipids as Non-Canonical TLR4 Agonists
por: Liang, Hong, et al.
Publicado: (2022)

Toll-Like Receptor (TLR2 and TLR4) Polymorphisms and Chronic Obstructive Pulmonary Disease
por: Budulac, Simona E., et al.
Publicado: (2012)

Expression of Toll-Like Receptors (TLR2 and TLR4) in the Eyes of Mice with Disseminated Acanthamoebiasis
por: Kot, Karolina, et al.
Publicado: (2019)

TLR2 and TLR4 in Parkinson’s disease pathogenesis: the environment takes a toll on the gut
por: Gorecki, Anastazja M., et al.
Publicado: (2021)

Endotoxin-tolerant Mice Have Mutations in Toll-like Receptor 4 (Tlr4)
por: Qureshi, Salman T., et al.
Publicado: (1999)

The Role of Carbohydrates in the Lipopolysaccharide (LPS)/Toll-Like Receptor 4 (TLR4) Signalling
por: Cochet, Florent, et al.
Publicado: (2017)

Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation
por: Tam, Janine S. Y., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ld5aqo83rhpgqeo0if0f6uhj02